Is Your Drug Discovery Strategy Missing a Critical Safety Signal?

Drug-induced liver injury (DILI) is one of the most common reasons for drug development failure, regulatory warnings, and market withdrawals. Despite advances in preclinical testing, many compounds still slip through early screens only to reveal hepatotoxicity later – when the stakes are higher and the costs are greater.

If you’re working in early-stage drug discovery, the question isn’t just how to detect toxicity – it’s how to detect it early and accurately. That’s where 3D spheroid models come in.

Why Traditional Models Fall Short

Primary human hepatocytes (PHHs) are considered the gold standard for in vitro liver toxicity studies. But when cultured in 2D, these cells rapidly lose their metabolic and transporter functions, limiting their predictive power. This decline can lead to false negatives, missed safety signals, and costly surprises down the line.

A Smarter Alternative: 3D Spheroid Cultures

Eurofins Discovery has developed a refined 3D spheroid hepatotoxicity assay using cryopreserved PHHs. These spheroids maintain liver-like functionality for extended periods, making them ideal for longer-term toxicity studies. In a recent validation study, the model was tested with 18 drugs – 15 known to cause DILI and 3 without DILI implications.

The results were compelling:

• Improved sensitivity for several high-risk compounds compared to 2D cultures.
• High specificity and positive predictive value, meaning fewer false positives.
• Better detection of delayed toxicity, thanks to a 7-day incubation period.

Why This Matters for You

If you’re just beginning to explore how to improve safety screening in your pipeline, this model offers a powerful starting point. It helps you:

• Catch hepatotoxic compounds earlier, before investing in costly development.
• Reduce reliance on animal models, aligning with ethical and regulatory trends.
• Improve confidence in your candidate selection, with more human-relevant data.

Whether you’re screening for mitochondrial toxicity, reactive metabolite formation, or bile acid disruption, the 3D spheroid model provides a more accurate and scalable solution.

Start Building a Safer Pipeline

Early awareness of DILI risk can transform your development strategy. With the right tools, you can make smarter decisions, reduce attrition, and bring safer therapies to market faster.